The One Step Test for NAGL is intended for use together with the FIA8000 Quantitative Immunoassay Analyzer (FIA8000). The product employs colloidal gold immunochromatogrphy to determine NGAL in human urine specimen. Monoclonal antibody and polyclonal antibody are employed to identify NGAL specifically, resulting in a purplish red streak appears on the test line. The color intensity of the test line increases in proportion to the concentrations of NGAL.
Then insert test card into the FIA8000 Quantitative Immunoassay Analyzer, the concentration of NGAL is measured quantitatively and displayed on the screen. The result can be transmitted to the lab or hospital information system.
Clinical applications
1. An early diagnostic marker for Acute Kidney Injury (AKI);
2. Diagnosis and warning for chronic kidney disease (CKI);
3. Monitoring the treatment effect and assessment of Lesion extent;
4. Tissue specificity in neoplastic diseases;
5. Associate with the development and occurance of CVD.
Any interests or questions, please contact us.
Tel：+86-25-68568594
E-mail:sales@getein.com.cn
Website:http://www.bio-gp.com.cn/EN/Index.aspx
bio-equip.cn
Getein Biotech, Inc. (SSE stock code:603387) is a fully integrated in vitro diagnostic company that develops, manufactures and distributes analytical medical devices as well as a broad range of innovative diagnostic test kits, dedicated to making diagnostics more accessible, more affordable, and more equitable for humanity. Since its foundation in 2002, Getein Biotech has launched 10 advanced technology platforms and possesses more than 200 independent intellectual property products. Headquartered in Nanjing, China, Getein Biotech has grown steadily and rapidly in North and South America, Europe, Africa, and the Asia-Pacific region. At present, the products and services of Getein Biotech are available in over 140 countries.
中文
